3-Methyladenine (3-MA)

Catalog No.S2767 Synonyms: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

Size Price Stock Quantity  
USD 70 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 17 Publications

6 Customer Reviews

  • granulosa cells (GCs) with 24 h of melatonin (10 μM) treatment were rinsed in PBS, and then exposed to H2O2 (200 μM) for 2 h. The autophagy inhibitor 3-MA (10 mM), or the apoptosis inhibitor Z-VAD-FMK (50 μM) were added 1 h prior to H2O2 incubation. Cell viability was determined using the CCK-8 assay. Data represent mean ± S.E; n = 3 in each group. *P < 0.05 (**P < 0.01) vs. vehicle group at 0 h. # Represents P < 0.05 (## Represents P < 0.01) vs. H2O2-only-treated cells. & Represents P > 0.05 vs. H2O2-only-treated cells. N, not significant, P > 0.05. δ Represents P < 0.05 (δδ Represents P < 0.01) vs. Z-VAD-FMK-treated cells.

    Redox Biol, 2018, 18:138-157. 3-Methyladenine (3-MA) purchased from Selleck.

    MDC-labeled vacuoles were induced by AZD2014 and inhibited by autophagy inhibitor (3-MA). SMMC-7721 cells were treated with AZD2014 or rapamycin at concentrations of 100 and 600 nM, respectively, for 48 hours in the presence or absence of 3-MA, and then stained with MDC. Cells were immediately observed under a confocal microscope. Cells in the control group were treated with DMSO. bars, 20 μm.

    Am J Cancer Res, 2015, 5(1): 125-139. 3-Methyladenine (3-MA) purchased from Selleck.

  • Cells were treated with DMSO, TDCIPP (100 μM) only, or pretreated with 3-MA before treatment with TDCIPP (100 μM). LC3 conversion and beclin-1 and p62 expression were assessed by western blotting at 24 h

    Food Chem Toxicol, 2017, 100:183-196. 3-Methyladenine (3-MA) purchased from Selleck.

    PC-9/ER cells were treated with CX-4945 (5 mM) for 48 h in the presence or absence of 3-MA (2 mM) and Atg7 siRNA (100 nM). Cleavage of PARP-1 and caspase-3 was shown by Western blot analysis. CT: without CX-4945; CX: CX-4945; CX+G: CX-4945 + gefitinib; CX+E: CX-4945 + erlotinib.

    PLoS One, 2014, 9(12): e114000 . 3-Methyladenine (3-MA) purchased from Selleck.

  • After getting treated with 10 μM compound C for indicated time periods with or without 50 μM 3-MA (C) pre-treatment for 1 h, the levels of indicated proteins in QBC939 and RBE cells were analyzed using Western blot.

    J Cell Biochem, 2017, 119(7):5538-5550. 3-Methyladenine (3-MA) purchased from Selleck.

    A: The survival ratio of AML12 cells was measured after treatment with rapamycin or 3-MA; B: Western blot was used to detect the expression of LC3 and P62 in AML12 cells treated with Rapamycin or 3-MA.

    World J Gastroenterol, 2016, 22(18): 4501-4514.. 3-Methyladenine (3-MA) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D NYTmT5hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGzcW0> NYLBeVY{Omh? M2X0dmROW09? M1vtV5Jm\HWlZYOg[5Jwf3SqIHnubIljcXSxcomg[YZn\WO2IH;mJGJFVUN? Moq3NlU4OTZ3NkG=
A549  M2HzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PvXFNuVQ>? MXuybC=> MlnZSG1UVw>? M1LVXpJm\HWlZYOg[5Jwf3SqIHnubIljcXSxcomg[YZn\WO2IH;mJGJFVUN? NWLMT5ZmOjV5MU[1OlE>
95D MXfBdI9xfG:|aYOgRZN{[Xl? MUm1cW0> M4SyUFJp M{\WTmROW09? MVTpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? NF;HOFIzPTdzNkW2NS=>
A549  MYrBdI9xfG:|aYOgRZN{[Xl? NEC5eY82dU1? MoOwNog> M{[ySGROW09? NEfOdmNqdmirYnn0d{BDTE2FLXnu[JVk\WRiYYDvdJRwfGmlIHPlcIwh\GWjdHi= MXSyOVcyPjV4MR?=
NBL-W-S  M3;XTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTTNY1O MkG0Oog> MVTlcohidmOnczDHRW5VNTZzIITvfIlkcXS7 NVPuOJJEOjV|MkOyNlI>
NBL-W-S  NXG0b3A6SXCxcITvd4l{KEG|c3H5 MWqxcW0> MmnGOog> MlTYbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgS2FPXC14MR?= NXK2bmlFOjV|MkOyNlI>
A2780cp  NXr2SFhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTTNY1O Mof1NYg> NISwSWRqdmO{ZXHz[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NV;aPYhmOjV|MkK2PVQ>
A549  NFfoZZlHfW6ldHnvckBCe3OjeR?= MmO5OY1O MmrVNog> M2LhO5N2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> MV2yOVI5PTZ{OB?=
H157 M3fPUGZ2dmO2aX;uJGF{e2G7 M1zFcVVuVQ>? M3S0b|Jp M1rKcpN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> NWradmRXOjV{OEW2Nlg>
MDR NIXwZY1CeG:ydH;zbZMhSXO|YYm= NIXjZY8yOG2P MXW2bC=> NVLyRWtZe3S{ZX7neIhmdnNidHjlJJBwf2W{IH;mJIFvfGmlYX7j[ZIh\HK3Z4O= MYOyOVAyQTdyMR?=
HT-29  MnnmRZBweHSxc3nzJGF{e2G7 MV[xcW0> MVi0PIg> NEnTb2FFVVOR MV3lcohidmOnczDic5J1\XqxbXniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> MnnENlQ5PDJzNUi=
Microglia  NWXyfmg1SXCxcITvd4l{KEG|c3H5 NGDGVGM2dU1? MX[yOIg> MXjk[YNz\WG|ZYOgbJlxd3irYT3pcoR2[2WmIHPlcIwh\GWjdHi= MlrWNlQ5OTh4MEG=
A2780cp NV\ER|Q3SXCxcITvd4l{KEG|c3H5 M2Ow[VIvPW2P MUGxbC=> NXXqcZk4\GSKMl:= NWfzd5Zu\W6qYX7j[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NF;IU5gzPDhzN{m0Oi=>
HepG2 MUDGeY5kfGmxbjDBd5NigQ>? M3m3VFVuVQ>? NVjleFU5PGh? NFX4VYNqdmO{ZXHz[ZMhUExicnXs[YF{\Q>? NXjmVmxkOjR5MUO1PFc>
A549 MkWwRZBweHSxc3nzJGF{e2G7 MX:1cW0> NGrqeXY1QGh? MXzk[YNz\WG|ZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdCCmZXH0bEBidmRiZYjwdoV{e2mxbjDs[ZZmdHNib3[gZ4F{eGG|ZT2zMEBD\WOuaX6tNUBidmRiTFOzMWlK NXzaV4RVOjR5ME[zNFM>
U2OS MXLBdI9xfG:|aYOgRZN{[Xl? MlLRNVBuVQ>? MYGyOIg> NFPHXllqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h? M33zclI1PjN7MEGz
Saos-2 M4f0WmFxd3C2b4Ppd{BCe3OjeR?= NVvqWXg3OTCvTR?= Ml\JNlRp NVf1ZZJIcW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJI9nKHSqZTDVNm9UKGOnbHzzJIlv\HWlZXSgZpkhTG:6 MlW1NlQ3OzlyMUO=
A549 Ml63RZBweHSxc3nzJGF{e2G7 M3j5[lExdU1? M1jT[VQ5cA>? MULhZ4NmdGW{YYTld{B1cGVicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgVHRZ MX6yOFYzPjd{Mh?=
HCT116  NUHacGw3SXCxcITvd4l{KEG|c3H5 MnLzOY1O NYj1UZBwOjSq M{\UOYVvcGGwY3XzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDhdIlo\W6rbh?= NFPTWXYzPDZ{NkWyNi=>
HGC-27 NE\vW2VHfW6ldHnvckBCe3OjeR?= M1XFNVExdU1? MUGxbC=> NXjtPIlLcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGyxc4OgZpkhWkGGMECxJI9zKE2NLUKyNFY> M{PjWlI1PDF4M{S5
U2OS  MkLDSpVv[3Srb36gRZN{[Xl? M3XKd|AvPS9zbV2= MmjqOFhp M1LyUIlv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ NWjHe2hmOjR|NUizOFI>
MG-63 M1PvVWZ2dmO2aX;uJGF{e2G7 MU[wMlUwOW2P MVK0PIg> MoP2bY5lfWOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> Mly2NlQ{PTh|NEK=
MG-63 M4D6OWFxd3C2b4Ppd{BCe3OjeR?= M3n6UVAvPS9zbV2= MVOzNog> NGrKT|FmdmijbnPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygZZBweHSxc3nz NFLkT24zPDN3OEO0Ni=>
MG-63 M{DhNWFxd3C2b4Ppd{BCe3OjeR?= NVPsSFZ3OTCvTR?= MmfvNVJp M3S2fIVvcGGwY3XzJGRRNWmwZIXj[YQh[XCxcITvd4l{ NWjINI1zOjR|NUizNFE>
NTUB1 M4\GN2Fxd3C2b4Ppd{BCe3OjeR?= NHXYUHM2dU1? NFPMN2cyNjWq MoDudI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ MUmyOFM1QTF5Nh?=
T24 MYLBdI9xfG:|aYOgRZN{[Xl? NFLD[FQ2dU1? NYf5SnBtOS53aB?= NEj0NI1xd3SnboTpZZRmeyClZXzlZ495cWJvaX7keYNm\CCjcH;weI9{cXN? NFLvTXkzPDN2OUG3Oi=>
SGC-7901  M1zpV2Fxd3C2b4Ppd{BCe3OjeR?= NFXBTnEzdU1? MnzoNYg> MmHZbY5kemWjc3XzJGNCNTRiaX7keYNm\CCjcH;weI9{cXN? MknvNlQ{OjF|NEC=
SMMC-7721 MYLBdI9xfG:|aYOgRZN{[Xl? MnTXNo1O NXftS|ZjOWh? NED3[2pqdmO{ZXHz[ZMhS0FvNDDpcoR2[2WmIHHwc5B1d3Orcx?= NYPrNoNFOjR|MkGzOFA>
ECSCs  NF:3UHZCeG:ydH;zbZMhSXO|YYm= M3XYVFExdU1? NHvwZYo1cA>? Mm\j[IVkemWjc3XzJJJieGGveXPpck11emWjdHXkJIFxd3C2b4Ppdy=> Ml3BNlQ{OTlzMEm=
MCF-7  NX\WUYlGTnWwY4Tpc44hSXO|YYm= Mn75NVBuVQ>? MkPtNlRp MVTpcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JIRzfWe| NEGyWZczPDNzNUW3PC=>
UOK257 MlfVRZBweHSxc3nzJGF{e2G7 M3vEUVVuVQ>? NFGwbWg{cA>? Mors[Y5p[W6lZYOgdIFkdGm2YYjlcE1u\WSrYYTl[EBieG:ydH;zbZPDqA>? M3Hu[FI1OzB3NkC0
ACHN-5968 NIe2ZoJCeG:ydH;zbZMhSXO|YYm= NIO2bFc2dU1? NF;5NpA{cA>? NY\Dc4Zw\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= MoCxNlQ{ODV4MES=
Huh7 NEPQWXFCeG:ydH;zbZMhSXO|YYm= NXPwS3lQOm2P M{TQelEzcA>? M3OyXmROW09? NGTHNm9qdmirYnn0d{BCYkR6MEW1MYlv\HWlZXSgZ4VtdCCmZXH0bC=> M2DycFI1Ojl5M{Cw
Hep3B NFL2WXhCeG:ydH;zbZMhSXO|YYm= MVmycW0> Ml6yNVJp NVezeIdnTE2VTx?= NEe2fJZqdmirYnn0d{BCYkR6MEW1MYlv\HWlZXSgZ4VtdCCmZXH0bC=> M4q3e|I1Ojl5M{Cw
RKO MVvGeY5kfGmxbjDBd5NigQ>? NVjBeGxsOm2P MUexbC=> M3jYb2ROW09? NGr6Z4xmdmijbnPld{Bk\WyuIHTlZZRpKGK7IHflcIRidmGveXPpci=> MWmyOFI6OTd5Nx?=
HepG2 E47 NWXRV3ZqTnWwY4Tpc44hSXO|YYm= NX;JPWFDOi53bV2= MYm0PIg> NGjDU2JqdmO{ZXHz[ZMhfGinIITvfIlkcXS7IH;mJGFCNCCEU1:sJIFv\CCFQ3y0 MYiyOFI4Ozd|OB?=
LoVo  M2riW2Fxd3C2b4Ppd{BCe3OjeR?= NGXaUXg2dU1? NVu3bGw{PDiq MoHH[Y5p[W6lZYOgSGNCNWmwZIXj[YQh[XCxcITvd4l{Ng>? NEfwWHgzPDJyMUixNi=>
WiDr Mlu1SpVv[3Srb36gRZN{[Xl? NWjBfppXOTCvTR?= NHvnPVMycA>? Mn;ibY5pcWKrdIOgVGNDVC2rbnT1Z4VlKEyFMzDJTUBmgHC{ZYPzbY9v M{K5TFI1OTlyNEi5
H1299  NEDtPXlHfW6ldHnvckBCe3OjeR?= MXSxNI1O M1nzOlRp M{DWSIlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp NUT2dnNROjRzN{OyNFg>
H460 NHn6T|RHfW6ldHnvckBCe3OjeR?= NGTSZm4yOG2P MmnIOIg> NHTwb5ZqdmO{ZXHz[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? MlP0NlQyPzN{MEi=
A549 NIDnR3dHfW6ldHnvckBCe3OjeR?= NXXhVpBVOTCvTR?= NYi4[mc{PGh? NWnPRpRocW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliaYLyZYRq[XSrb36= MYmyOFE1Ojd|NR?=
Hep3B MojBRZBweHSxc3nzJGF{e2G7 NWG2Oos6PW2P NXfIbmdWOjSq MXHheJRmdnWjdHXzJHRPTi4QsTDwdo91\WO2aX;uJIFo[Wmwc4Sgd4VzfW1ic4ThdpZifGmxbj3t[YRq[XSnZDDhdI9xfG:|aYO= MVGyOFA3PjZ7Mx?=
SMMC-7721 NUnwUHNlSXCxcITvd4l{KEG|c3H5 M{nFWVVuVQ>? MUiyOIg> MmnNZZR1\W63YYTld{BVVkZvzsGgdJJwfGWldHnvckBi\2GrboP0JJNmenWvIIP0ZZJ3[XSrb36tcYVlcWG2ZXSgZZBweHSxc3nz NF\3VmczPDB4Nk[5Ny=>
HO8910 NFLhVWFCeG:ydH;zbZMhSXO|YYm= M3S1XFExdU1? M12yVVEzcA>? M2nycIVvcGGwY3XzJGIyQS2rbnT1Z4VlKGGyb4D0c5Nq M2HVTFI{QTh|NkGw
MCF7 NHjSb4FHfW6ldHnvckBCe3OjeR?= NFqxfJM2dU1? NHfKeXMzPGh? M3nMd4lv[3KnYYPld{BEfU9iaX7keYNm\CClZXzsJIRm[XSq NXuyb2lKOjN7NkK2Nlk>
HONE-1  NVnEfmtuTnWwY4Tpc44hSXO|YYm= NF7te2Y2dU1? NGjvSo0ycA>? MlnQdoVxemW|c3XzJFZzNW2nZHnheIVlKFKRUzDwdo9lfWO2aX;u MWiyN|g6OjN3OB?=
HeLa Mo[5SpVv[3Srb36gRZN{[Xl? MlfxNVBuVQ>? NEjuUVkzcA>? NWLibWFne3WycILld5NmeyCOQ{OgTWkh\XiycnXzd4l{d25? NF3nVGUzOzh4NEezPC=>
HepG2 NIXMcXBHfW6ldHnvckBCe3OjeR?= MYGxNI1O NFTvNXIzPGh? NF7PVJlqdmirYnn0d{B{cVSLR1HSMUBidmRiSFLTV{1qdmS3Y3XkJIF2fG:yaHHnfS=> M2DoZVI{QDF5MESw
SH-SY5Y NGfqVnRHfW6ldHnvckBCe3OjeR?= M33EUVFuVQ>? NF30[nAzPGh? MYPpcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF;DVC=> NFTLTnIzOzd2M{G0PC=>
SH-SY5Y MUHBdI9xfG:|aYOgRZN{[Xl? NWfCd|AzPW2P MoO2NYg> MkjKZYJwdGm|aHXzJINmdGG|dILvcEBv\XW{b4Dyc5Rm[3SrdnWg[YZn\WO2 Mm[2NlM3OTl|OUW=
PC12  M3vWPWZ2dmO2aX;uJGF{e2G7 MXGxNI1O NWfDWnVuOjSq MVL3ZZRmeg>? NYjVSllLyqCrbnjpZol1eyClaIntc5RzgXC|aX6tcIls\SCycn;0[YF{d22jbDDhZ5Rqfmm2eT6= MVSyN|YxOzl5OR?=
OV2008 NG\D[3ZCeG:ydH;zbZMhSXO|YYm= M1uwelVuVQ>? MnHJNlRp MUDjc453\XK2czDGWHk4OjBid3n0bEBETESSIHnueI8h[W5iYXTkbZRqfmViZX\m[YN1KHSxd3Hy[JMhc2mubHnu[{BwfmG{aXHuJINidmOncjDj[Yxtew>? MlPpNlM2QTJ{OEG=
A2780 MnHBRZBweHSxc3nzJGF{e2G7 MVi1cW0> MYKyOIg> NGfUfpdkd264ZYL0d{BHXFl5MkCge4l1cCCFRFTQJIlvfG9iYX6gZYRlcXSrdnWg[YZn\WO2IITve4Fz\HNia3nscIlv\yCxdnHybYFvKGOjbnPldkBk\Wyucx?= NFHxOpozOzV7MkK4NS=>
Saos-2  NXP6d2dtSXCxcITvd4l{KEG|c3H5 NULvUYJbOW2P NVnTNGJ1QT[q NF7ZVpZqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IGDDXC=> NX\oeoVNOjN3NkOxO|E>
1321N1 M2mzOmN6fG:2b4jpZ4l1gSCDc4PhfS=> NVvj[VhGPW2P NX2ycoZ4OjSq MYXwdo91\WO2czDj[YxtKGGpYXnud5QhWEOQLXnu[JVk\WRidH;4bYNqfHl? Mly1NlM2OjV{NkW=
SH-SY5Y NVSzdIFzS3m2b4TvfIlkcXS7IFHzd4F6 NVK2NphDPW2P NWW5THEyOjSq NGrpRY9qdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 MXmyN|UzPTJ4NR?=
HT-29  MWjGeY5kfGmxbjDBd5NigQ>? MkX0NY1O MXO0PE86Pmh? NYrTWVUycW6qaXLpeJMhSU2SSzDpcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> MmT1NlM2ODh{N{K=
OR6 MV7GeY5kfGmxbjDBd5NigQ>? NFXPfGwyOG2P MYS3Nog> MoDTd5VxeHKnc4Pld{BJS1ZicnXwcIlk[XSrb36gZY5lKG[xcn3heIlwdiCxZjDheZRweGijZ3;zc41mew>? MmfLNlM{QTV6N{W=
Hela  MlqySpVv[3Srb36gRZN{[Xl? MlnEOY1O MV:yOIg> NUfnTJROcW6qaXLpeJMhe3Sjco\heIlwdi2rbnT1Z4VlKGG3dH;wbIFogQ>? MnLrNlM{QTV4N{m=
MCF-7  NUnpWGNCTnWwY4Tpc44hSXO|YYm= MV[1cW0> NVXwOYpEOjSq MV3pcohq[mm2czDzeIFzfmG2aX;uMYlv\HWlZXSgZZV1d3CqYXf5 NXrre5ZzOjN|OUW2O|k>
HUVECs M4HiemZ2dmO2aX;uJGF{e2G7 NIfFOGg{dU1? NFv0e3MzPGh? NVnjZnJv[myxY3vzJJRp\SCycn;0[YN1cX[nIHXm[oVkfCCxZjDy[ZN3\XKjdILvcEBjgSCrbnjpZol1cW6pIHH1eI9xcGGpeR?= MX2yN|M2QDl{OB?=
T24 M1v0W2Z2dmO2aX;uJGF{e2G7 NEPRfm8yOG2P M4XJb|Fp M17McJJm\HWlZYOgeIhmKGOuZXH2ZYdmKG:oIFzDN{Bi\nSncjDiZYlk[WyrbjD0doVifG2nboS= Mn:5NlM{PTRyOEC=
U251MG  MXfGeY5kfGmxbjDBd5NigQ>? M4jCelNuVQ>? M4XYblFp Mnz2d5VxeHKnc4Pld{BNSzNvSVmgdJJwfGWrbjDlfJBz\XO|aX;u Mn;vNlM{Ozh4MUi=
GTL-16  MVTBdI9xfG:|aYOgRZN{[Xl? MXG1cW0> M{DheFI1cA>? MkDYdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjczDjc41x[XKnZDD0c{Bk\WyuczD0doVifGWmIIfpeIghVUWWIHnubIljcXSxcoO= NWr5NohIOjN|MUO0PVA>
T-47D MXLGeY5kfGmxbjDBd5NigQ>? NIDtVW4yOG2P MnjINog> MYHpcohq[mm2czDheZRweGijZ4mgdJJw[2W|czDhcoQhcW6lcnXhd4V{KHKjcHHtfYNqdiCrbnT1Z4VlKGGyb4D0c5Nqew>? MmLzNlM{ODByMk[=
PaCa44 NUKwTG5oSXCxcITvd4l{KEG|c3H5 NEHaN|QzNjWvTR?= MW[xbC=> Mn;PdoVlfWOnc9Mg[4VvcXCrbj3t[YRq[XSnZDDhdI9xfG:|aYO= NIPSUXQzOzF{NEGxNi=>
MDA-MB231 M{C5TGZ2dmO2aX;uJGF{e2G7 NHH3U|E2dU1? M2DaeFFp MorybY5kemWjc3XzJJJme3[ncnH0do9tNW2nZHnheIVlKGOjc4Dhd4Uh[WO2aY\heIlwdiCjbnSgZ4VtdCCmZXH0bC=> MV2yN|A5QDh3MB?=
HeLa M{P3cmFxd3C2b4Ppd{BCe3OjeR?= NEPVWFUyOG2P NV75coZLOmh? MX3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliY3:teJJm[XSvZX70JJdqfGhiUFXJ MkPNNlMxODBzM{W=
SK-HEP-1 MWrBdI9xfG:|aYOgRZN{[Xl? MUGxNI1O NEnzVIYycA>? MVPwdo91\WO2czDh[4FqdnO2IHH1eI9xcGGpeTDhcoQhcW6mdXPld{BieG:ydH;zbZMhcW5iYoXmZYxqdi22cnXheIVlKGOnbHzz MmTINlI5PTh4NEm=
HepG2 MWDBdI9xfG:|aYOgRZN{[Xl? MortN41O M2HIeVVp NXLGeWU6emWmdXPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHFFew>? NFG5SWYzOjh|NkW5OS=>
MCF-7  NVzOOHhiTnWwY4Tpc44hSXO|YYm= NX;Weok1Om2P NEnTVY8zPGh? NUn2S4dLcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> NXzzPGZKOjR7N{C2O|Y>
MDA-MB-231 NVO2eYFsTnWwY4Tpc44hSXO|YYm= MWWycW0> MVGyOIg> NGPHN49qdmirYnn0d{BifXSxcHjh[5khcW6mdXPl[EBjgSCWTdMg MYqyOFk4ODZ5Nh?=
MCF-7  NV2xTYx1TnWwY4Tpc44hSXO|YYm= MWSycW0> M2PlNVQ5cA>? MmmxdJJwdW:2ZYOgWG0ucW6mdXPl[EBk\WyuIHTlZZRp NEfO[nEzPDl5ME[3Oi=>
MDA-MB-231 M17a[WZ2dmO2aX;uJGF{e2G7 MUKycW0> MoTFOFhp NGfQNHFxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? Ml30NlQ6PzB4N{[=
PANC-1  NXKySFNFSXCxcITvd4l{KEG|c3H5 MWexcW0> NVztbJJrPDiq NGnYfIpFVVOR M3HHVYVvcGGwY3XzJIJwenSnen;tbYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ NILoVWIzPDh2MkG1PC=>
MDA-MB 231 MnK2RZBweHSxc3nzJGF{e2G7 NVzobVNiPW2P MUKwMlVp MkWxcY9lfWyjdHXzJHRw[2:vaX9CsuKhcW6mdXPl[EBieG:ydH;zbZM> NHzwU|AzPDh|MEe4NS=>
Microglia  NFnpN3ZCeG:ydH;zbZMhSXO|YYm= M17Ie|VuVQ>? MViyOIg> NEjnTXJl\WO{ZXHz[ZMhcHmyb4jpZU1qdmS3Y3XkJINmdGxiZHXheIg> MnvnNlQ5OTh4MEG=
A2780cp MkPwRZBweHSxc3nzJGF{e2G7 NFvMTWYzNjWvTR?= MVOxbC=> Moi5[IRJOk9? MnvF[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NXnOXFg4OjR6MUe5OFY>
HepG2 Mn3OSpVv[3Srb36gRZN{[Xl? NGDQdVY2dU1? MUW0bC=> M1S1VYlv[3KnYYPld{Bk\WyudXzhdkBt\X[nbIOgc4YhUE{EoB?= NVzZPFNxOjR5MUO1PFc>
U2OS MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULQfG9QOTCvTR?= NWTJcXRROjSq NYXQNFJRcW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJIlv\HWlZXSgZpkhTG:6 MnrUNlQ3OzlyMUO=
HCT116 MmW3RZBweHSxc3nzJGF{e2G7 M1v6dFVuVQ>? MVuyOIg> MXLEUXNQ NFnNW2tmdmijbnPld{BieGmpZX7pck1qdmS3Y3XkJINmdGxiZHXheIg> MkPxNlQ3OjZ3MkK=
MCF-7  M{\EfGFxd3C2b4Ppd{BCe3OjeR?= MkjzNE4ydU1? NVvGS41JPmh? NEj4[phmdmijbnPld{B{cXK2aX7vcE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MnLYNlI4PTF7OEm=
PC-3  M1nFW2Fxd3C2b4Ppd{BCe3OjeR?= M1;tbFJuVQ>? Mo[2Nog> NWnN[o5GcW6lcnXhd4V{KE:UST3pcoR2[2WmIHPlcIwh\GWjdHi= MoiwNlI4PDV3OEC=
U251  NGXhfYRCeG:ydH;zbZMhSXO|YYm= M2D3T|VuVQ>? MVyyOIg> NFnHSIdqdmO{ZXHz[ZMhWzFvaX7keYNm\CClZXzsJIRm[XSq MX[yNlU4QTd6OB?=
HeLa  MVPBdI9xfG:|aYOgRZN{[Xl? MX61cW0> M17UNVI1cA>? MWXpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHPlcIwh\GWjdHi= MV6yNlU1PTF{OB?=
A549 Ml;TSpVv[3Srb36gRZN{[Xl? MnS3NE4ydU1? MljQNlRp M3HycJN2eHC{ZYPz[ZMhW1VzMUK3OE1qdmS3Y3XkJINmdGxiZHXheIg> NFH6TnIzOjR4Nkm2NC=>
pDCs NV\ITHN3TnWwY4Tpc44hSXO|YYm= NUDZR4pPOTCvTR?= NWLteZprOC53aB?= NX7COYJRyqC{ZXT1Z4V{KHSqZTDpcoR2[3Srb36gc4YhUU[QLd8xJIJ6KHO|Ul7BOFA> NVH1UXAyOjJ|OU[1PVk>
BGC-823 MUXGeY5kfGmxbjDBd5NigQ>? NF\IVnA2dU1? NG\DR2YzcA>? Mk\mbY5pcWKrdIOgeIhmKHKjdHWgc4Yh[XW2b4DoZYdq[yClZXzsdy=> MkDnNlI{OjJzNUK=
U937 NUPYXnBzTnWwY4Tpc44hSXO|YYm= MVmycW0> NULWR|k4OTKq NIK1fnBl\WO{ZXHz[ZMhfGinIHH1eI9xcGGpeTDyZZRqd8Li NI\qN4UzOjF3NUG1NC=>
Marc-145 MYDGeY5kfGmxbjDBd5NigQ>? NXuzdnN1PW2P NFfIPZEyOi9{ND:zOog> NVLTO3R7emWmdXPld{B1cGViUGLSV3YhfGm2ZYLzJIFv\CC2aHWgdJJwfGWrbjDlfJBz\XO|aX;u NID4NGkzOjFzOUmwNC=>
HBx  MYfBdI9xfG:|aYOgRZN{[Xl? MUGxNI1O MX60PIg> MVzEUXNQ NVTKXVM{cW6lcnXhd4V{KGOnbHyg[IVifGh? MkTMNlIxOjByN{i=
MCF-7 M1zSV2Z2dmO2aX;uJGF{e2G7 MUGxNI1O NYHCWGlKPDiq M{\VZYJtd2OtczDheZRweGijZ4mgbY5lfWOnZDDifUBjd3K2ZYrvcYlj NIWxTHQzOTl|MUmzOy=>
RMPI8226  NYTlUINQTnWwY4Tpc44hSXO|YYm= NUDC[I5{PW2P MoTxNYg> M4jaZZN2eHC{ZYPz[ZMhfGinIHzleoVtKG:oIHH1eI9xcGGpeTD1coRmeiCwdYTybYVvfCCmZYDs[ZRqd25? MkDuNlE6OTV4MkC=
PC12/TetOn MUnGeY5kfGmxbjDBd5NigQ>? M1LLflAvOS9zbV2= MVKxPIg> NU\PS2xZdGWjZIOgeI8h|rFvc4nuLHdVMSCjY3P1cZVt[XSrb36sJJRwgGmlaYT5MEBidmRib3zp[49u\XJiZn;ycYF1cW:wwrC= NFPzcZQzOTlyNk[1PS=>
HeLa  M4e5ZmN6fG:2b4jpZ4l1gSCDc4PhfS=> M4fSfVJuVQ>? MV2yOIg> NFm0[oNqdmirYnn0[ZMhfGinIHP5eI91d3irY3n0fUBw\iC|aXzpZolvcW5idH:gTIVN[SClZXzsd{4> NWfpUY84OjF6N{WzPFU>
Jurkat NWfPNmpzTnWwY4Tpc44hSXO|YYm= NHf0OWQyOG2P Mn3FNYg> Momw[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= MXmyNVg3PDB|Nx?=
K562 NVn4boRSTnWwY4Tpc44hSXO|YYm= NWrCVHU3OTCvTR?= NWq1fHRWOWh? Mmnw[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= NVXsfG4yOjF6NkSwN|c>
Nara-H NWKwRpBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j6fFVuVQ>? MnPsOFhp MoHa[Y5p[W6lZYOgeIVue2m{b3zpcZV{dWWmaXH0[YQhe3WycILld5Nqd25ib3[gUoFz[S2KIHPlcIwheHKxbHnm[ZJifGmxbh?= M3;QeFIyQDB3MEOz
HUVECs MY\GeY5kfGmxbjDBd5NigQ>? NHXBZ2YyOG2P M{m5R|AvPWh? M173c4Rm[3KnYYPld{B1cGViQVfFMWJUSWmwZIXj[YQh[XW2b4DoZYd6KGyndnW= MYqyNVQ3QDV7Mh?=
HepG2 NWS3XZBnSXCxcITvd4l{KEG|c3H5 MXmycW0> Mn7lNYg> MlPz[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MmLqNlE1PTN4OUG=

... Click to View More Cell Line Experimental Data

In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
+ Expand

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
+ Expand
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
+ Expand
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Formulation: Saline
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID